|Day Low/High||2.80 / 2.98|
|52 Wk Low/High||1.19 / 3.09|
Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity
In recent trading, shares of BioScrip Inc have crossed above the average analyst 12-month target price of $2.40, changing hands for $2.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Q1 Consolidated Revenue of $217.8 Million, loss from continuing operations net of income taxes of $19.0 million and Adjusted EBITDA of $5.2 Million
Appoints Stephen M. Deitsch as Senior Vice President, Chief Financial Officer and Treasurer
Company Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare
Betting on negative reaction to the Fed has not worked well in the past.
Q4 Consolidated Revenue of $240.1 Million, loss from continuing operations net of income taxes of ($5.2) million and Adjusted EBITDA of $9.5 Million
BioScrip, Inc. (NASDAQ:BIOS), a leading national provider of infusion and home care management solutions, announced today it has joined a newly established coalition, Keep My Infusion Care at Home, which spans...
Here's a technical look at how to trade several under $10 stocks that could trigger big breakout trades soon.
The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 1,957,677 share increase in total short interest for BioScrip Inc , to 15,238,636, an increase of 14.74% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The most recent short interest data was recently released for the 11/30/2016 settlement date, and BioScrip Inc is one of the most shorted stocks of the Russell 3000, based on 10.63 "days to cover" versus the median component at 5.21. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Provides Update on Fourth Quarter 2016 and Comments on Business Impact of 21st Century Cures Act
Q3 Consolidated Revenue of $224.5 Million, Loss from continuing operations, net of income taxes of $(11.1) Million and Adjusted EBITDA of $3.5 Million
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in BioScrip Inc , where a total volume of 5,006 contracts has been traded thus far today, a contract volume which is representative of approximately 500,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 76.5% of BIOS's average daily trading volume over the past month, of 654,660 shares.
Insiders at these companies have been scooping up shares of their own stock recently.